Weisel, K. Dimopoulos, M. Moreau, P. Yagci, M. Larocca, A. Kanate, A.S. Vural, F. Cascavilla, N. Basu, S. Johnson, P. Byeff, P. Hus, M. Rodríguez-Otero, P. Muelduer, E. Anttila, P. Hayden, P.J. Krauth, M.-T. Lucio, P. Ben-Yehuda, D. Mendeleeva, L. Guo, S. Yu, X. Grote, L. Biyukov, T. Dhanasiri, S. Richardson, P., Health-related quality-of-life results from the phase 3 OPTIMISMM study: pomalidomide, bortezomib, and low-dose dexamethasone versus bortezomib and low-dose dexamethasone in relapsed or refractory multiple myeloma, Clinical Lymphoma Myeloma and Leukemia, (61), 1850-1859, 2020, Taylor and Francis Ltd.,